How the Genetic Nature of Lp(a) Levels Influences Screening

Experts discuss the genetic determinants of lipoprotein(a) (Lp[a]) levels, providing evidence supporting this conclusion. They also explore how the hereditary nature of Lp(a) can drive awareness of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis risk, potentially influencing screening protocols.

EP: 1.Lp(a) in ASCVD and Guideline Recommendations

EP: 2.Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP: 3.The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP: 4.Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP: 5.Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

Now Viewing

EP: 6.How the Genetic Nature of Lp(a) Levels Influences Screening

EP: 7.A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP: 8.The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP: 9.Evidence Supporting 2024 Guidance for Lp(a) Testing

EP: 10.Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP: 11.Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

Video content above is prompted by the following:

• I mentioned in the introduction that a person’s Lp(a) levels are mostly determined by genetics. What evidence supports this conclusion?
• How might the hereditary nature of Lp(a) help drive awareness of risk for ASCVD and aortic stenosis and influence screening protocols?

Related Videos

Related Content

Advertisement

April 24th 2025

Abelacimab Demonstrates Safety and Efficacy for Patients With AFib of All Ages: Sid Patel, MD

Kyle Munz Siddharth M. Patel, MD, MPH

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated Sid Patel, MD.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

April 8th 2025

Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD

Kyle Munz Jeremy Wigginton, MD

Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.

May 10th 2022

For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management

On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.

April 2nd 2025

Digital Solutions Can Transform CVD Care, Prevention

Kyle Munz

Mobile self-management programs like that offered by Hello Heart can benefit employers and patients alike as they seek to manage and prevent heart disease.

March 24th 2025

Raising Awareness of Lp(a) to Improve Heart Disease Treatment Approaches

Kyle Munz Nathan Wong, PhD

Lipoprotein(a) [Lp(a)] plays a key role in assessing cardiovascular risk, making awareness efforts equally essential for prevention and early intervention.

Related Content

Advertisement

April 24th 2025

Abelacimab Demonstrates Safety and Efficacy for Patients With AFib of All Ages: Sid Patel, MD

Kyle Munz Siddharth M. Patel, MD, MPH

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated Sid Patel, MD.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

April 8th 2025

Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD

Kyle Munz Jeremy Wigginton, MD

Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.

May 10th 2022

For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management

On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.

April 2nd 2025

Digital Solutions Can Transform CVD Care, Prevention

Kyle Munz

Mobile self-management programs like that offered by Hello Heart can benefit employers and patients alike as they seek to manage and prevent heart disease.

March 24th 2025

Raising Awareness of Lp(a) to Improve Heart Disease Treatment Approaches

Kyle Munz Nathan Wong, PhD

Lipoprotein(a) [Lp(a)] plays a key role in assessing cardiovascular risk, making awareness efforts equally essential for prevention and early intervention.